Management of breakthrough bleeding in extended hormonal contraceptive regimens

Details for Australian Patent Application No. 2005237255 (hide)

Owner Bayer Schering Pharma Aktiengesellschaft

Inventors Sachse, Andreas

Agent Davies Collison Cave

Pub. Number AU-B-2005237255

PCT Pub. Number WO2005/105103

Priority 60/566,443 30.04.04 US; 60/575,024 28.05.04 US; 60/577,199 07.06.04 US; 60/638,380 27.12.04 US; 60/660,068 10.03.05 US

Filing date 29 April 2005

Wipo publication date 10 November 2005

Acceptance publication date 7 July 2011

International Classifications

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/567 (2006.01) - substituted in position 17 alpha, e.g. mestranol, norethandrolone

A61K 31/57 (2006.01) - substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone

A61K 31/575 (2006.01) - substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

A61K 31/585 (2006.01)

A61P 15/18 (2006.01) Drugs for genital or sexual disorders

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/105103 Priority application(s): WO2005/105103

23 June 2011 Alteration of Name

  The name of the applicant has been altered to Bayer Schering Pharma Aktiengesellschaft

7 July 2011 Application Accepted

  Published as AU-B-2005237255

3 November 2011 Alteration of Name

  The name of the patentee has been altered to Bayer Pharma Aktiengesellschaft

3 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005237256-MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy

2005237254-Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor